Qu Biologics Granted Broad Australian Patent for Targeted Treatment of Multiple Cancers
22. Januar 2014 10:10 ET
|
Qu Biologics
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jan. 22, 2014) - Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs) that aim to reboot the body's...
Qu Biologics Appoints Rashieda Gluck as Vice President, Clinical Operations
11. Dezember 2013 11:05 ET
|
Qu Biologics
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Dec. 11, 2013) - Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs) that aim to 'reboot' the...
Qu Biologics Granted Broad European Patent for Targeted Treatment of Multiple Cancers
06. Dezember 2013 05:30 ET
|
Qu Biologics
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Dec. 6, 2013) - Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs) that aim to reboot the body's...
Qu Biologics Appoints Dr. David Mullins as Chief Scientific Officer
04. Dezember 2013 09:45 ET
|
Qu Biologics
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Dec. 4, 2013) - Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs) that aim to 'reboot' the body's...
Qu Biologics Begins Research with McMaster University to Study New Crohn's Disease Research Model
03. Dezember 2013 10:00 ET
|
Qu Biologics
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Dec. 3, 2013) - Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs) that aim to stimulate the...
Qu Biologics Begins Research With McMaster University to Study Chronic Inflammation Associated With Macrophage Dysfunction
15. August 2013 12:42 ET
|
Qu Biologics
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Aug. 15, 2013) - Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs) that aim to "reboot" the...
Qu Biologics Introduces Travel Subsidy Program for Crohn's Clinical Trial Participants
30. Juli 2013 12:00 ET
|
Qu Biologics
VANCOUVER, BRITISH COLUMBIA--(Marketwired - July 30, 2013) - Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs) that aim to "reboot" the...
Qu Biologics Initiates Study of Site Specific Immunomodulators at Geisel School of Medicine at Dartmouth
03. Juli 2013 12:00 ET
|
Qu Biologics
VANCOUVER, BRITISH COLUMBIA--(Marketwired - July 3, 2013) - Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs) that aim to "reboot" the body's...
Qu Biologics Appoints Former Novartis President Mr. Robert Pelzer to its Board of Directors
13. Juni 2013 13:41 ET
|
Qu Biologics
VANCOUVER, BRITISH COLUMBIA--(Marketwired - June 13, 2013) - Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs) that aim to "reboot" the...
Qu Biologics Enrolls First Patient in Phase 1/2 Clinical Trial of QBECO SSI for the Treatment of Crohn's Disease
11. Juni 2013 16:22 ET
|
Qu Biologics
VANCOUVER, BRITISH COLUMBIA--(Marketwired - June 11, 2013) - Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs) that aim to "reboot" the...